The anti-tumor activity of the combination therapy involves the reduced expression of EGFR, proliferation marker Ki-67, and the cluster of differentiation CD31, which provides a rationale for future clinical investigations [284] The epidermal growth factor receptor (EGFR) is highly expressed in OSCC and drugs blocking EGFR proteins are used in cancer therapy. Here, EGFR is linked to neoplasm.